Scottsdale, AZ (PRWEB) July 29, 2010
MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled “Thought Leader Insight & Analysis: Pain/Analgesics,” designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for treatments and devices in this disease area.
“This new report summarizes the consensus findings from interviews with U.S-based anesthesiologists,” according to MedPredict CEO Elizabeth Mathews. “This panel identifies unmet needs in the treatment of acute and chronic pain, shares current favorite approaches to managing pain, and surveys the clinical development pipeline.”
This report is divided into five sections: General Findings, Devices, On-Market/Established Mechanisms, Early Pipeline, and Less Likely to Work.
The On-Market section captures some thoughts on opioids, SNRI, GABA and COX2 approaches. “Opioids remain the standard of care for the management of severe pain, both acute and chronic, continues Mathews. “The panel addresses the balance between meeting this medical need and the non-medical ramifications associated with addiction and diversion. In the chronic setting constipation is a major drawback of opioid use. In both the chronic and acute settings, there is also a concern over life threatening respiratory depression. Panelists talk about their favorite new approaches to mitigate, in particular, the respiratory toxicity.”
In the Early Pipeline section, the reader will find comments on nerve growth factor antibodies, ampakines, sodium channel blockers, cathepsin K antagonists, compliment antagonists (C5a), calcitonin gene related peptide receptor antagonists, NMDA antagonists and cannabinoids (CB-1).
In the Less Likely to Work section, the panelists suggest approaches that have not panned out, or that are likely to have class related toxicities that should give pause to companies trying to develop new agents. These included: TRPV1 / vanilloids, Substance P/NK-1 and sodium channel blockers.
Products/mechanisms mentioned in this report:
Intrathecal neuromodulation (electrostimulation)
Intrathecal pumps
Intrathecal gabapentin
Opioid: morphine, morphine/naltrexone, hydromorphone, fentanyl, oxycodone, hydrocodone, tramadol, tapentadol, methylnaltrexone
SNRI: duloxetine, milnacipran
GABA: gabapentin, pregabalin, sodium oxybate
NSAID / COX2: celecoxib, valdecoxib, rofecoxib
Ampakine: CX-717
Voltage gated sodium channel: liposomal saxitoxin, NAB-17 (19, 13, 18)
Nerve Growth Factor: tanezumab, REGN-475 / SAR-164877
Antiresorptives: odanacatib, bisphosphonates
Compliment antagonists: CCX-168
Calcitonin gene-related peptide receptor antagonists: olcegepant, telcagepant
NMDA: flupirtine, ketamine, d-methadone
Cannabinoid: CB-1 agonist
Substance-P; NK-1
TRPV1
Companies discussed in this report: Acura, Adeona, Advanced Neuromodulation Systems/St. Jude, Alpharma, Astellas, Biovail, Boehringer Ingelheim, Boston Scientific, ChemoCentryx, Cortex, Covidien, Cypress,Forest Laboratories, GlaxoSmithKline,Grunenthal, Janssen, Jazz Pharmaceuticals, King Pharmaceuticals, Lilly, Meda, Medtronic, Merck, Ortho-McNeil, Pfizer, Pierre Fabre, Pipex, Progenics, Purdue, Regeneron, Sanofi Aventis, Valeant, and Xenoport.
The full report may be purchased by contacting MedPredict.
About MedPredict
MedPredict (www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders. Based on primary interviews with these thought leaders, MedPredict publishes periodic therapeutic area reports to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and presentations, as well as clinical, regulatory and marketing activity.
For more information contact:
Elizabeth Mathews
MedPredict
513.271.1924
